HUTCHMED (China) (HCM) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 245.2% versus a loss of 10.6%. MBX Biosciences is the larger company by market cap ($2.53 billion vs $2.39 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | MBX |
|---|---|---|
| Share price | $13.76 | $52.53 |
| Market cap | $2.39B | $2.53B |
| 1-day change | -3.64% | -3.69% |
| YTD return | +7.13% | +72.92% |
| 1-year return | -10.64% | +245.19% |
| 5-year return | -55.79% | — |
| P/E ratio (TTM) | 137.60 | — |
| Forward P/E | 53.08 | — |
| EPS (TTM) | $0.10 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | $-87.00M |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $72.64 |
| 52-week low | $9.77 | $12.94 |
| Distance from 52-week high | -15.74% | -27.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +59.96% | +79.52% |
| Average volume | 67.70K | 539.34K |
| Shares outstanding | 173.81M | 48.16M |
| Employees | 1,790 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed HCM by 255.8 percentage points over the past year.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
HCM vs MBX FAQ
Which is bigger, HUTCHMED (China) or MBX Biosciences?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.53B compared with $2.39B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or MBX?
MBX returned +245.19% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.